BCL2 and breast carcinoma: Nonetheless, since the levels of CDK6, and the prosurvival protein BCL2 were modulated upon BORA silencing and inhibitors of these pathways are FDA-approved drugs for breast cancer and leukemia [44,45], we sought to ascertain whether the combination of these inhibitors could mimic the BORA depletion phenotype and thus could result in beneficial therapeutic effects for OC patients.